Respiratory System Drugs — MCQs

Q: Vitamin K is involved in the post-translational modification of which amino acid?

Glutamate. **Explanation:** **1. Why Glutamate is Correct:** Vitamin K acts as a vital cofactor for the enzyme **gamma-glutamyl carboxylase**. This enzyme is responsible for the post-translational modification of specific **glutamate (Glu)** residues on certain proteins, converting them into **gamma-carboxyglutamate (Gla)** residues. This carboxylation adds a second negative charge to the glutamate side chain, which is essential for the protein's ability to bind **calcium ions (Ca²⁺)**. In the context of coagulation, this calcium binding allows clotting factors to anchor to phospholipid membranes, a critical step in the coagulation cascade. **2. Why Other Options are Incorrect:** * **Aspartate:** While chemically similar to glutamate, aspartate is not a substrate for Vitamin K-dependent carboxylation. * **Glycine:** This is the simplest amino acid and lacks the carboxyl side chain required for this specific modification. * **GABA (Gamma-Aminobutyric Acid):** GABA is an inhibitory neurotransmitter derived from glutamate via decarboxylation, not a target for Vitamin K-mediated post-translational modification. **3. High-Yield Clinical Pearls for NEET-PG:** * **Vitamin K-Dependent Factors:** Factors **II, VII, IX, X**, and anticoagulant proteins **C and S**. * **Mechanism of Warfarin:** Warfarin inhibits **Vitamin K Epoxide Reductase (VKOR)**, preventing the recycling of Vitamin K and thus inhibiting the gamma-carboxylation of glutamate residues. * **Osteocalcin:** Beyond clotting, Vitamin K is also required for the carboxylation of osteocalcin in bones, which is necessary for bone mineralization. * **Laboratory Marker:** Deficiency or Warfarin use leads to the production of **PIVKA** (Proteins Induced by Vitamin K Absence/Antagonism), which are functionally inactive factors.

Q: A night shift worker complains of profuse rhinorrhea and sneezing for the past few days. Which among the following drugs can be given to him?

Fexofenadine. **Explanation:** The patient is a **night shift worker** presenting with symptoms of allergic rhinitis (rhinorrhea and sneezing). The primary clinical consideration here is the side effect profile of antihistamines, specifically **sedation and psychomotor impairment**. **1. Why Fexofenadine is correct:** Fexofenadine is a **Second-Generation Antihistamine (SGA)**. Unlike first-generation agents, SGAs are highly polar, have low lipid solubility, and are substrates for the P-glycoprotein efflux pump. This prevents them from crossing the blood-brain barrier (BBB) in significant amounts. Fexofenadine is specifically classified as a **"non-sedating"** antihistamine because it is devoid of CNS depressant effects even at higher doses. For a night shift worker, maintaining alertness is crucial for safety and performance. **2. Why the other options are incorrect:** * **Promethazine, Chlorpheniramine, and Pheniramine** are all **First-Generation Antihistamines**. These drugs are highly lipid-soluble and readily cross the BBB. They cause significant sedation, drowsiness, and impairment of concentration by blocking H1 receptors in the CNS. Using these in a shift worker could lead to occupational hazards or accidents. **High-Yield Clinical Pearls for NEET-PG:** * **Fexofenadine** is the active metabolite of Terfenadine. It lacks the cardiotoxic risk (QT prolongation/Torsades de pointes) associated with its parent drug. * **Cetirizine** is a second-generation agent but is known to cause "mild sedation" in some patients compared to Fexofenadine or Loratadine. * **Bilastine and Mizolastine** are other newer non-sedating antihistamines frequently tested. * **Azelastine** is a topical (nasal spray) H1 blocker often used for rapid relief in allergic rhinitis.

Q: A child suffering from asthma is to be treated with a drug that blocks the synthesis of leukotrienes. What drug would be an appropriate choice?

Zileuton. ### Explanation The correct answer is **Zileuton**. **Mechanism of Action:** Leukotrienes (LTB4, LTC4, LTD4, and LTE4) are potent inflammatory mediators derived from arachidonic acid via the **5-Lipoxygenase (5-LOX)** pathway. Zileuton is a specific inhibitor of the 5-LOX enzyme, thereby directly **blocking the synthesis** of all leukotrienes. This reduction in leukotriene production helps decrease bronchoconstriction, airway edema, and mucus secretion in asthmatic patients. **Analysis of Incorrect Options:** * **Montelukast (Option B):** While this is a leukotriene modifier, it does not block synthesis. Instead, it is a **Leukotriene Receptor Antagonist (LTRA)** that selectively blocks the **CysLT1 receptor**. It prevents leukotrienes from binding to their target but does not stop their production. * **Cromolyn sodium (Option A):** This is a **Mast Cell Stabilizer**. It prevents the degranulation of mast cells and the subsequent release of histamine and leukotrienes but does not inhibit the biochemical synthesis pathway of leukotrienes. * **Theophylline (Option D):** A methylxanthine that acts primarily as a **Phosphodiesterase (PDE) inhibitor** and adenosine receptor antagonist, leading to increased cAMP and bronchodilation. It has no direct effect on leukotriene synthesis. **High-Yield NEET-PG Pearls:** * **Zileuton Side Effect:** It is associated with **hepatotoxicity** (elevation of liver enzymes); therefore, periodic LFT monitoring is required. * **Aspirin-Exacerbated Respiratory Disease (AERD):** Leukotriene modifiers (Zileuton/Montelukast) are the drugs of choice for "Aspirin-induced asthma." * **Zafirlukast vs. Montelukast:** Zafirlukast inhibits CYP2C9 and CYP3A4, whereas Montelukast has fewer drug interactions and is more commonly used in children.

Q: Which of the following is a leukotriene antagonist?

Montelukast. Explanation: **Correct Answer: D. Montelukast** **Mechanism of Action:** Leukotrienes (specifically $LTC_4, LTD_4,$ and $LTE_4$) are potent bronchoconstrictors and inflammatory mediators [1]. **Montelukast** and **Zafirlukast** act as selective and competitive **CysLT₁ receptor antagonists** [2]. By blocking these receptors on bronchial smooth muscle, they prevent bronchoconstriction, airway edema, and mucus secretion. They are primarily used for the prophylaxis of bronchial asthma and the management of aspirin-induced asthma [2]. **Analysis of Incorrect Options:** * **A. Nicorandil:** This is a **potassium channel opener** with nitrate-like activity. It is used as an anti-anginal drug, not in respiratory pathology. * **B. Zileuton:** While it acts on the leukotriene pathway, it is a **5-Lipoxygenase (5-LOX) inhibitor**, not a receptor antagonist [1]. It prevents the synthesis of leukotrienes from arachidonic acid. * **C. Sodium Cromoglycate:** This is a **Mast Cell Stabilizer**. It prevents the degranulation of mast cells and the subsequent release of histamine and leukotrienes but does not block leukotriene receptors directly. **NEET-PG High-Yield Pearls:** * **Aspirin-Exacerbated Respiratory Disease (AERD):** Leukotriene modifiers (like Montelukast) are the drugs of choice for asthma patients sensitive to NSAIDs/Aspirin [2]. * **Churg-Strauss Syndrome:** A rare but high-yield association; systemic vasculitis has been reported in patients following the use of Zafirlukast/Montelukast (often during corticosteroid withdrawal). * **Administration:** Montelukast is preferred over Zafirlukast because it is taken **once daily** and does not require periodic liver function monitoring (unlike Zileuton).

Q: What is the recommended dose of MgSO4 in asthma?

2 g infused over 20 minutes. **Explanation:** **1. Why Option B is Correct:** Intravenous Magnesium Sulfate ($MgSO_4$) is used as an adjunctive therapy in **acute severe asthma** that does not respond to initial treatment with inhaled bronchodilators and systemic corticosteroids. The standard recommended dose is **2 g IV infused over 20 minutes**. * **Mechanism of Action:** Magnesium acts as a calcium channel blocker; it inhibits calcium uptake into bronchial smooth muscle cells, leading to **bronchodilation**. It also inhibits acetylcholine release from nerve endings and stabilizes mast cells, reducing inflammatory mediator release. **2. Why Other Options are Incorrect:** * **Option A & D (8 g and 6 g):** These doses are excessively high for asthma management. Such high doses are closer to the loading doses used in Eclampsia (Prichard’s regimen) and carry a high risk of **magnesium toxicity**, leading to loss of deep tendon reflexes, respiratory depression, and cardiac arrest. * **Option C (2 g over 40 minutes):** While the dose is correct, the infusion rate is slower than the standard emergency protocol. In acute severe asthma (status asthmaticus), a 20-minute infusion is the established clinical guideline to achieve rapid therapeutic serum levels. **3. High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Reserved for patients with $FEV_1$ <25-30% of predicted or those who fail to respond to initial therapy. * **Monitoring:** Always monitor the **Patellar reflex (Knee jerk)**, respiratory rate, and urine output when administering $MgSO_4$. * **Antidote:** In case of toxicity, the antidote is **10% Calcium Gluconate (10 ml IV)**. * **Nebulized Magnesium:** While IV is standard, isotonic nebulized $MgSO_4$ is sometimes used as an adjuvant to Salbutamol, though evidence is less robust than IV.

Q: Which of the following is a short-acting antihistamine?

Promethazine. **Explanation:** The duration of action of antihistamines depends on their pharmacokinetic profile and receptor affinity. **Promethazine** is a first-generation H1-antihistamine characterized by its relatively short duration of action (typically 4–6 hours). Unlike newer agents, first-generation antihistamines are highly lipid-soluble, cross the blood-brain barrier, and dissociate from receptors more rapidly, necessitating more frequent dosing. **Analysis of Options:** * **Promethazine (Correct):** A short-acting, first-generation antihistamine. It is highly sedative and possesses significant anti-emetic, anti-cholinergic, and local anesthetic properties. * **Cetirizine (Incorrect):** A second-generation antihistamine. It is long-acting (duration >24 hours) due to its slow dissociation from the H1 receptor, allowing for once-daily dosing. * **Hydroxyzine (Incorrect):** A first-generation antihistamine, but it has a longer duration of action (approx. 12–24 hours) compared to promethazine and is often used for chronic pruritus or anxiety. * **Acrivastine (Incorrect):** While it has a short half-life, it is a second-generation agent often categorized as "intermediate-acting." In the context of this specific comparison, Promethazine is the classic representative of short-acting agents. **NEET-PG High-Yield Pearls:** * **Promethazine** is the drug of choice for **motion sickness** and morning sickness (as part of the Doxylamine combination). * **First-generation H1 blockers** (e.g., Diphenhydramine, Chlorpheniramine) are prone to causing sedation and "anticholinergic side effects" (dry mouth, urinary retention). * **Second-generation H1 blockers** (e.g., Fexofenadine, Loratadine) are non-sedating because they are poor lipophiles and are substrates for the P-glycoprotein efflux pump in the blood-brain barrier. * **Fexofenadine** is the active metabolite of Terfenadine and is considered the least sedating antihistamine.

Q: Ivacaftor was approved by FDA for which condition?

Cystic fibrosis. **Explanation:** **Ivacaftor** is a breakthrough medication in the management of **Cystic Fibrosis (CF)**. It is classified as a **CFTR Potentiator**. Cystic fibrosis is caused by mutations in the *Cystic Fibrosis Transmembrane Conductance Regulator* (CFTR) gene, which leads to defective chloride ion transport across epithelial membranes. Ivacaftor works by increasing the "open-probability" time of the CFTR channel on the cell surface, thereby enhancing chloride transport and improving hydration of the airway surface liquid. It was initially approved for patients with the **G551D mutation** (the "gatekeeper" mutation). **Analysis of Incorrect Options:** * **B. Migraine:** Treatment typically involves triptans (5-HT1B/1D agonists), CGRP antagonists (Erenumab), or NSAIDs. Ivacaftor has no effect on neurovascular pathways. * **C. Hypertension:** Managed with diuretics, ACE inhibitors, ARBs, or Calcium Channel Blockers. Ivacaftor does not influence systemic vascular resistance or blood pressure. * **D. Glycogen storage disorders:** These are metabolic enzyme deficiencies (e.g., Von Gierke’s) managed primarily through dietary modifications and enzyme replacement, not ion channel modulation. **Clinical Pearls for NEET-PG:** * **Combination Therapy:** Ivacaftor is often combined with **Lumacaftor** or **Tezacaftor** (CFTR correctors) for the more common **F508del mutation**. * **Mechanism:** It addresses the *function* of the protein at the surface, whereas "correctors" address the *folding and trafficking* of the protein. * **Metabolism:** It is a substrate of **CYP3A4**; therefore, dosage adjustments are required when administered with CYP3A4 inhibitors (like ketoconazole) or inducers (like rifampin).

Q: Bronchial asthma is associated with raised levels of which of the following substances?

Leukotrienes. **Explanation:** **Bronchial asthma** is a chronic inflammatory airway disease characterized by bronchoconstriction, airway hyperresponsiveness, and mucus hypersecretion. The correct answer is **Leukotrienes (LTs)**, specifically the cysteinyl leukotrienes (LTC4, LTD4, and LTE4). 1. **Why Leukotrienes are correct:** In asthma, mast cells and eosinophils release leukotrienes via the 5-lipoxygenase (5-LOX) pathway of arachidonic acid metabolism. These are potent bronchoconstrictors (1000 times more potent than histamine), increase vascular permeability (causing edema), and stimulate mucus secretion. 2. **Why other options are incorrect:** * **PGI2 (Prostacyclin):** A potent vasodilator and inhibitor of platelet aggregation; it does not play a primary role in asthma pathogenesis. * **PGE2:** Generally acts as a bronchodilator and has anti-inflammatory properties in the lungs. A deficiency, rather than an excess, is sometimes linked to aspirin-exacerbated respiratory disease (AERD). * **Thromboxane (TXA2):** Primarily involved in platelet aggregation and vasoconstriction. While it has some bronchoconstrictor effects, it is not the hallmark mediator elevated in asthma. **High-Yield Clinical Pearls for NEET-PG:** * **Zileuton:** Inhibits the enzyme 5-LOX, preventing leukotriene synthesis. * **Montelukast/Zafirlukast:** Selective antagonists of the **CysLT1 receptor**. They are particularly effective in aspirin-induced asthma and exercise-induced bronchospasm. * **Aspirin-Induced Asthma:** Occurs because NSAIDs inhibit the COX pathway, "shunting" arachidonic acid toward the LOX pathway, leading to an overproduction of leukotrienes.

Q: What is the antidote for heparin overdose?

Protamine sulfate. **Explanation:** **Correct Answer: A. Protamine Sulfate** Protamine sulfate is the specific pharmacological antagonist used to reverse the effects of heparin. It is a highly basic (cationic) protein derived from fish sperm. Heparin is a highly acidic (anionic) molecule. When administered, protamine binds to heparin through a **chemical antagonism** mechanism (ionic bonding) to form a stable, inactive salt complex, thereby neutralizing its anticoagulant effect. It is most effective against Unfractionated Heparin (UFH) and only partially reverses Low Molecular Weight Heparin (LMWH). **Incorrect Options:** * **B. Phylloquinone (Vitamin K1):** This is the antidote for **Warfarin** overdose. It promotes the hepatic synthesis of clotting factors II, VII, IX, and X, which are inhibited by coumarin derivatives. * **C & D. Ticlopidine and Clopidogrel:** These are **P2Y12 receptor inhibitors** (antiplatelet drugs). They inhibit platelet aggregation and have no role in reversing anticoagulation; rather, they increase bleeding risk. **High-Yield Clinical Pearls for NEET-PG:** * **Dosing:** 1 mg of protamine neutralizes approximately 100 units of heparin. * **Protamine Paradox:** Protamine itself has weak anticoagulant properties. If given in significant excess (without heparin to bind to), it can inhibit platelets and clotting factors, worsening a bleeding diathesis. * **Adverse Effects:** Rapid IV injection can cause histamine release leading to hypotension, bradycardia, and pulmonary hypertension. * **Monitoring:** The effectiveness of heparin reversal is monitored using the **Activated Clotting Time (ACT)** or **aPTT**.

Respiratory System Drugs Indian Medical PG Practice Questions and MCQs

Question 1: Vitamin K is involved in the post-translational modification of which amino acid?

A. Glutamate (Correct Answer)
B. Aspartate
C. Glycine
D. GABA

Explanation: **Explanation:** **1. Why Glutamate is Correct:** Vitamin K acts as a vital cofactor for the enzyme **gamma-glutamyl carboxylase**. This enzyme is responsible for the post-translational modification of specific **glutamate (Glu)** residues on certain proteins, converting them into **gamma-carboxyglutamate (Gla)** residues. This carboxylation adds a second negative charge to the glutamate side chain, which is essential for the protein's ability to bind **calcium ions (Ca²⁺)**. In the context of coagulation, this calcium binding allows clotting factors to anchor to phospholipid membranes, a critical step in the coagulation cascade. **2. Why Other Options are Incorrect:** * **Aspartate:** While chemically similar to glutamate, aspartate is not a substrate for Vitamin K-dependent carboxylation. * **Glycine:** This is the simplest amino acid and lacks the carboxyl side chain required for this specific modification. * **GABA (Gamma-Aminobutyric Acid):** GABA is an inhibitory neurotransmitter derived from glutamate via decarboxylation, not a target for Vitamin K-mediated post-translational modification. **3. High-Yield Clinical Pearls for NEET-PG:** * **Vitamin K-Dependent Factors:** Factors **II, VII, IX, X**, and anticoagulant proteins **C and S**. * **Mechanism of Warfarin:** Warfarin inhibits **Vitamin K Epoxide Reductase (VKOR)**, preventing the recycling of Vitamin K and thus inhibiting the gamma-carboxylation of glutamate residues. * **Osteocalcin:** Beyond clotting, Vitamin K is also required for the carboxylation of osteocalcin in bones, which is necessary for bone mineralization. * **Laboratory Marker:** Deficiency or Warfarin use leads to the production of **PIVKA** (Proteins Induced by Vitamin K Absence/Antagonism), which are functionally inactive factors.

Question 2: A night shift worker complains of profuse rhinorrhea and sneezing for the past few days. Which among the following drugs can be given to him?

A. Promethazine
B. Fexofenadine (Correct Answer)
C. Chlorpheniramine
D. Pheniramine

Explanation: **Explanation:** The patient is a **night shift worker** presenting with symptoms of allergic rhinitis (rhinorrhea and sneezing). The primary clinical consideration here is the side effect profile of antihistamines, specifically **sedation and psychomotor impairment**. **1. Why Fexofenadine is correct:** Fexofenadine is a **Second-Generation Antihistamine (SGA)**. Unlike first-generation agents, SGAs are highly polar, have low lipid solubility, and are substrates for the P-glycoprotein efflux pump. This prevents them from crossing the blood-brain barrier (BBB) in significant amounts. Fexofenadine is specifically classified as a **"non-sedating"** antihistamine because it is devoid of CNS depressant effects even at higher doses. For a night shift worker, maintaining alertness is crucial for safety and performance. **2. Why the other options are incorrect:** * **Promethazine, Chlorpheniramine, and Pheniramine** are all **First-Generation Antihistamines**. These drugs are highly lipid-soluble and readily cross the BBB. They cause significant sedation, drowsiness, and impairment of concentration by blocking H1 receptors in the CNS. Using these in a shift worker could lead to occupational hazards or accidents. **High-Yield Clinical Pearls for NEET-PG:** * **Fexofenadine** is the active metabolite of Terfenadine. It lacks the cardiotoxic risk (QT prolongation/Torsades de pointes) associated with its parent drug. * **Cetirizine** is a second-generation agent but is known to cause "mild sedation" in some patients compared to Fexofenadine or Loratadine. * **Bilastine and Mizolastine** are other newer non-sedating antihistamines frequently tested. * **Azelastine** is a topical (nasal spray) H1 blocker often used for rapid relief in allergic rhinitis.

Question 3: A child suffering from asthma is to be treated with a drug that blocks the synthesis of leukotrienes. What drug would be an appropriate choice?

A. Cromolyn sodium
B. Montelukast
C. Zileuton (Correct Answer)
D. Theophylline

Explanation: ### Explanation The correct answer is **Zileuton**. **Mechanism of Action:** Leukotrienes (LTB4, LTC4, LTD4, and LTE4) are potent inflammatory mediators derived from arachidonic acid via the **5-Lipoxygenase (5-LOX)** pathway. Zileuton is a specific inhibitor of the 5-LOX enzyme, thereby directly **blocking the synthesis** of all leukotrienes. This reduction in leukotriene production helps decrease bronchoconstriction, airway edema, and mucus secretion in asthmatic patients. **Analysis of Incorrect Options:** * **Montelukast (Option B):** While this is a leukotriene modifier, it does not block synthesis. Instead, it is a **Leukotriene Receptor Antagonist (LTRA)** that selectively blocks the **CysLT1 receptor**. It prevents leukotrienes from binding to their target but does not stop their production. * **Cromolyn sodium (Option A):** This is a **Mast Cell Stabilizer**. It prevents the degranulation of mast cells and the subsequent release of histamine and leukotrienes but does not inhibit the biochemical synthesis pathway of leukotrienes. * **Theophylline (Option D):** A methylxanthine that acts primarily as a **Phosphodiesterase (PDE) inhibitor** and adenosine receptor antagonist, leading to increased cAMP and bronchodilation. It has no direct effect on leukotriene synthesis. **High-Yield NEET-PG Pearls:** * **Zileuton Side Effect:** It is associated with **hepatotoxicity** (elevation of liver enzymes); therefore, periodic LFT monitoring is required. * **Aspirin-Exacerbated Respiratory Disease (AERD):** Leukotriene modifiers (Zileuton/Montelukast) are the drugs of choice for "Aspirin-induced asthma." * **Zafirlukast vs. Montelukast:** Zafirlukast inhibits CYP2C9 and CYP3A4, whereas Montelukast has fewer drug interactions and is more commonly used in children.

Question 4: Which of the following is a leukotriene antagonist?

A. Nicordanil
B. Zileuton
C. Sodium chromoglycate
D. Montelukast (Correct Answer)

Explanation: Explanation: **Correct Answer: D. Montelukast** **Mechanism of Action:** Leukotrienes (specifically $LTC_4, LTD_4,$ and $LTE_4$) are potent bronchoconstrictors and inflammatory mediators [1]. **Montelukast** and **Zafirlukast** act as selective and competitive **CysLT₁ receptor antagonists** [2]. By blocking these receptors on bronchial smooth muscle, they prevent bronchoconstriction, airway edema, and mucus secretion. They are primarily used for the prophylaxis of bronchial asthma and the management of aspirin-induced asthma [2]. **Analysis of Incorrect Options:** * **A. Nicorandil:** This is a **potassium channel opener** with nitrate-like activity. It is used as an anti-anginal drug, not in respiratory pathology. * **B. Zileuton:** While it acts on the leukotriene pathway, it is a **5-Lipoxygenase (5-LOX) inhibitor**, not a receptor antagonist [1]. It prevents the synthesis of leukotrienes from arachidonic acid. * **C. Sodium Cromoglycate:** This is a **Mast Cell Stabilizer**. It prevents the degranulation of mast cells and the subsequent release of histamine and leukotrienes but does not block leukotriene receptors directly. **NEET-PG High-Yield Pearls:** * **Aspirin-Exacerbated Respiratory Disease (AERD):** Leukotriene modifiers (like Montelukast) are the drugs of choice for asthma patients sensitive to NSAIDs/Aspirin [2]. * **Churg-Strauss Syndrome:** A rare but high-yield association; systemic vasculitis has been reported in patients following the use of Zafirlukast/Montelukast (often during corticosteroid withdrawal). * **Administration:** Montelukast is preferred over Zafirlukast because it is taken **once daily** and does not require periodic liver function monitoring (unlike Zileuton).

Question 5: What is the recommended dose of MgSO4 in asthma?

A. 8 g IV over 20 minutes
B. 2 g infused over 20 minutes (Correct Answer)
C. 2 g IV over 40 minutes
D. 6 g IV over 40 minutes

Explanation: **Explanation:** **1. Why Option B is Correct:** Intravenous Magnesium Sulfate ($MgSO_4$) is used as an adjunctive therapy in **acute severe asthma** that does not respond to initial treatment with inhaled bronchodilators and systemic corticosteroids. The standard recommended dose is **2 g IV infused over 20 minutes**. * **Mechanism of Action:** Magnesium acts as a calcium channel blocker; it inhibits calcium uptake into bronchial smooth muscle cells, leading to **bronchodilation**. It also inhibits acetylcholine release from nerve endings and stabilizes mast cells, reducing inflammatory mediator release. **2. Why Other Options are Incorrect:** * **Option A & D (8 g and 6 g):** These doses are excessively high for asthma management. Such high doses are closer to the loading doses used in Eclampsia (Prichard’s regimen) and carry a high risk of **magnesium toxicity**, leading to loss of deep tendon reflexes, respiratory depression, and cardiac arrest. * **Option C (2 g over 40 minutes):** While the dose is correct, the infusion rate is slower than the standard emergency protocol. In acute severe asthma (status asthmaticus), a 20-minute infusion is the established clinical guideline to achieve rapid therapeutic serum levels. **3. High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Reserved for patients with $FEV_1$ <25-30% of predicted or those who fail to respond to initial therapy. * **Monitoring:** Always monitor the **Patellar reflex (Knee jerk)**, respiratory rate, and urine output when administering $MgSO_4$. * **Antidote:** In case of toxicity, the antidote is **10% Calcium Gluconate (10 ml IV)**. * **Nebulized Magnesium:** While IV is standard, isotonic nebulized $MgSO_4$ is sometimes used as an adjuvant to Salbutamol, though evidence is less robust than IV.

Question 6: A 34-year-old patient has moderately severe new-onset asthma and is prescribed a selective beta-2 agonist inhaler. Which of the following signs can be observed in this patient after taking the medication?

A. Tachycardia
B. Skeletal muscle tremor
C. Hypoglycemia (Correct Answer)
D. Hypokalemia

Explanation: ### Explanation **Correct Option: C. Hypoglycemia** The question asks for a sign that can be observed following the administration of a selective $\beta_2$ agonist. $\beta_2$ receptors play a crucial role in metabolic regulation. Stimulation of these receptors in the liver and skeletal muscles promotes **glycogenolysis** (breakdown of glycogen to glucose) and **gluconeogenesis**. This leads to an increase in blood glucose levels (**Hyperglycemia**). Therefore, **Hypoglycemia** is the correct answer because it is the *opposite* of the expected physiological effect and represents an incorrect clinical sign in this context. **Analysis of Incorrect Options:** * **A. Tachycardia:** Even "selective" $\beta_2$ agonists can cause tachycardia. This occurs via two mechanisms: direct stimulation of $\beta_2$ receptors in the heart (which has a small population of $\beta_2$ receptors) and reflex tachycardia due to $\beta_2$-mediated peripheral vasodilation. * **B. Skeletal muscle tremor:** This is the **most common side effect** of $\beta_2$ agonists. It occurs due to direct stimulation of $\beta_2$ receptors located on the skeletal muscle fibers, which increases the speed of contraction and leads to tremors. * **D. Hypokalemia:** $\beta_2$ stimulation activates the **Na⁺/K⁺-ATPase pump**, causing an inward shift of potassium from the extracellular fluid into the cells (primarily skeletal muscle). This results in a decrease in serum potassium levels. **High-Yield NEET-PG Pearls:** * **Metabolic Effects:** $\beta_2$ agonists cause Hyperglycemia, Hypokalemia, and Hyperlactatemia. * **Clinical Use of Hypokalemia:** Due to their ability to shift potassium intracellularly, nebulized Salbutamol is used as an emergency treatment for **Hyperkalemia**. * **Tolerance:** Prolonged use of $\beta_2$ agonists leads to **downregulation (tachyphylaxis)** of receptors; this is why they are often co-prescribed with inhaled corticosteroids (ICS), which upregulate $\beta_2$ receptors.

Question 7: Which of the following is a short-acting antihistamine?

A. Cetirizine
B. Promethazine (Correct Answer)
C. Hydroxyzine
D. Acrivastine

Explanation: **Explanation:** The duration of action of antihistamines depends on their pharmacokinetic profile and receptor affinity. **Promethazine** is a first-generation H1-antihistamine characterized by its relatively short duration of action (typically 4–6 hours). Unlike newer agents, first-generation antihistamines are highly lipid-soluble, cross the blood-brain barrier, and dissociate from receptors more rapidly, necessitating more frequent dosing. **Analysis of Options:** * **Promethazine (Correct):** A short-acting, first-generation antihistamine. It is highly sedative and possesses significant anti-emetic, anti-cholinergic, and local anesthetic properties. * **Cetirizine (Incorrect):** A second-generation antihistamine. It is long-acting (duration >24 hours) due to its slow dissociation from the H1 receptor, allowing for once-daily dosing. * **Hydroxyzine (Incorrect):** A first-generation antihistamine, but it has a longer duration of action (approx. 12–24 hours) compared to promethazine and is often used for chronic pruritus or anxiety. * **Acrivastine (Incorrect):** While it has a short half-life, it is a second-generation agent often categorized as "intermediate-acting." In the context of this specific comparison, Promethazine is the classic representative of short-acting agents. **NEET-PG High-Yield Pearls:** * **Promethazine** is the drug of choice for **motion sickness** and morning sickness (as part of the Doxylamine combination). * **First-generation H1 blockers** (e.g., Diphenhydramine, Chlorpheniramine) are prone to causing sedation and "anticholinergic side effects" (dry mouth, urinary retention). * **Second-generation H1 blockers** (e.g., Fexofenadine, Loratadine) are non-sedating because they are poor lipophiles and are substrates for the P-glycoprotein efflux pump in the blood-brain barrier. * **Fexofenadine** is the active metabolite of Terfenadine and is considered the least sedating antihistamine.

Question 8: Ivacaftor was approved by FDA for which condition?

A. Cystic fibrosis (Correct Answer)
B. Migraine
C. Hypertension
D. Glycogen storage disorders

Explanation: **Explanation:** **Ivacaftor** is a breakthrough medication in the management of **Cystic Fibrosis (CF)**. It is classified as a **CFTR Potentiator**. Cystic fibrosis is caused by mutations in the *Cystic Fibrosis Transmembrane Conductance Regulator* (CFTR) gene, which leads to defective chloride ion transport across epithelial membranes. Ivacaftor works by increasing the "open-probability" time of the CFTR channel on the cell surface, thereby enhancing chloride transport and improving hydration of the airway surface liquid. It was initially approved for patients with the **G551D mutation** (the "gatekeeper" mutation). **Analysis of Incorrect Options:** * **B. Migraine:** Treatment typically involves triptans (5-HT1B/1D agonists), CGRP antagonists (Erenumab), or NSAIDs. Ivacaftor has no effect on neurovascular pathways. * **C. Hypertension:** Managed with diuretics, ACE inhibitors, ARBs, or Calcium Channel Blockers. Ivacaftor does not influence systemic vascular resistance or blood pressure. * **D. Glycogen storage disorders:** These are metabolic enzyme deficiencies (e.g., Von Gierke’s) managed primarily through dietary modifications and enzyme replacement, not ion channel modulation. **Clinical Pearls for NEET-PG:** * **Combination Therapy:** Ivacaftor is often combined with **Lumacaftor** or **Tezacaftor** (CFTR correctors) for the more common **F508del mutation**. * **Mechanism:** It addresses the *function* of the protein at the surface, whereas "correctors" address the *folding and trafficking* of the protein. * **Metabolism:** It is a substrate of **CYP3A4**; therefore, dosage adjustments are required when administered with CYP3A4 inhibitors (like ketoconazole) or inducers (like rifampin).

Question 9: Bronchial asthma is associated with raised levels of which of the following substances?

A. Leukotrienes (Correct Answer)
B. Prostaglandin I2 (PGI2)
C. Prostaglandin E2 (PGE2)
D. Thromboxane

Explanation: **Explanation:** **Bronchial asthma** is a chronic inflammatory airway disease characterized by bronchoconstriction, airway hyperresponsiveness, and mucus hypersecretion. The correct answer is **Leukotrienes (LTs)**, specifically the cysteinyl leukotrienes (LTC4, LTD4, and LTE4). 1. **Why Leukotrienes are correct:** In asthma, mast cells and eosinophils release leukotrienes via the 5-lipoxygenase (5-LOX) pathway of arachidonic acid metabolism. These are potent bronchoconstrictors (1000 times more potent than histamine), increase vascular permeability (causing edema), and stimulate mucus secretion. 2. **Why other options are incorrect:** * **PGI2 (Prostacyclin):** A potent vasodilator and inhibitor of platelet aggregation; it does not play a primary role in asthma pathogenesis. * **PGE2:** Generally acts as a bronchodilator and has anti-inflammatory properties in the lungs. A deficiency, rather than an excess, is sometimes linked to aspirin-exacerbated respiratory disease (AERD). * **Thromboxane (TXA2):** Primarily involved in platelet aggregation and vasoconstriction. While it has some bronchoconstrictor effects, it is not the hallmark mediator elevated in asthma. **High-Yield Clinical Pearls for NEET-PG:** * **Zileuton:** Inhibits the enzyme 5-LOX, preventing leukotriene synthesis. * **Montelukast/Zafirlukast:** Selective antagonists of the **CysLT1 receptor**. They are particularly effective in aspirin-induced asthma and exercise-induced bronchospasm. * **Aspirin-Induced Asthma:** Occurs because NSAIDs inhibit the COX pathway, "shunting" arachidonic acid toward the LOX pathway, leading to an overproduction of leukotrienes.

Question 10: What is the antidote for heparin overdose?

A. Protamine sulfate (Correct Answer)
B. Phylloquinone
C. Ticlopidine
D. Clopidogrel

Explanation: **Explanation:** **Correct Answer: A. Protamine Sulfate** Protamine sulfate is the specific pharmacological antagonist used to reverse the effects of heparin. It is a highly basic (cationic) protein derived from fish sperm. Heparin is a highly acidic (anionic) molecule. When administered, protamine binds to heparin through a **chemical antagonism** mechanism (ionic bonding) to form a stable, inactive salt complex, thereby neutralizing its anticoagulant effect. It is most effective against Unfractionated Heparin (UFH) and only partially reverses Low Molecular Weight Heparin (LMWH). **Incorrect Options:** * **B. Phylloquinone (Vitamin K1):** This is the antidote for **Warfarin** overdose. It promotes the hepatic synthesis of clotting factors II, VII, IX, and X, which are inhibited by coumarin derivatives. * **C & D. Ticlopidine and Clopidogrel:** These are **P2Y12 receptor inhibitors** (antiplatelet drugs). They inhibit platelet aggregation and have no role in reversing anticoagulation; rather, they increase bleeding risk. **High-Yield Clinical Pearls for NEET-PG:** * **Dosing:** 1 mg of protamine neutralizes approximately 100 units of heparin. * **Protamine Paradox:** Protamine itself has weak anticoagulant properties. If given in significant excess (without heparin to bind to), it can inhibit platelets and clotting factors, worsening a bleeding diathesis. * **Adverse Effects:** Rapid IV injection can cause histamine release leading to hypotension, bradycardia, and pulmonary hypertension. * **Monitoring:** The effectiveness of heparin reversal is monitored using the **Activated Clotting Time (ACT)** or **aPTT**.

Practice by Chapter

Bronchodilators

Practice Questions

Corticosteroids in Respiratory Disorders

Practice Questions

Anti-inflammatory Respiratory Agents

Practice Questions

Mast Cell Stabilizers

Practice Questions

Leukotriene Modifiers

Practice Questions

Antitussives and Expectorants

Practice Questions

Nasal Decongestants

Practice Questions

Pulmonary Surfactants

Practice Questions

Drugs for Pulmonary Hypertension

Practice Questions

Oxygen Therapy

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free